Asset
Dexamethasone Sodium Phosphate
Quince Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06193200 | phase3 | completed | 2024-06-24 | 2025-12-17 | Quince Therapeutics S.p.A. | Evaluate the Neurological Effects of EryDex on Subjects With A-T |
| NCT06664853 | phase3 | terminated | 2024-12-11 | 2026-01-30 | Quince Therapeutics S.p.A. | Open-Label Extension of EryDex Study IEDAT-04-2022 |
FDA applications (0)
This company has no applications containing this asset.